Trent, J. C., Wagner, A. J., Attia, S., Agulnik, M., Wilky, B. A., Tap, W. D., Mehren, M. V., Davis, E. J., Zou, L., Shah, N., Moynihan, K., Lawrence, J., Sun, L., Somaiah, N. (2025). Peak part 1 summary: A phase 3, randomized, open-label, multicenter clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.4_suppl.826